Apollo Endosurgery (APEN) Receiving Somewhat Positive Press Coverage, Study Shows

Media coverage about Apollo Endosurgery (NASDAQ:APEN) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.9350426855455 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several equities research analysts have recently issued reports on APEN shares. Zacks Investment Research raised shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. Northland Securities reaffirmed a “buy” rating and issued a $12.00 target price on shares of Apollo Endosurgery in a research report on Tuesday, November 28th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Apollo Endosurgery currently has a consensus rating of “Buy” and a consensus target price of $9.44.

Shares of Apollo Endosurgery (NASDAQ:APEN) opened at $4.27 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54. Apollo Endosurgery has a 12 month low of $3.55 and a 12 month high of $21.88.

In related news, VP Bret Schwartzhoff bought 9,500 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was bought at an average price of $4.24 per share, for a total transaction of $40,280.00. Following the purchase, the vice president now owns 15,631 shares in the company, valued at approximately $66,275.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 74.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Apollo Endosurgery (APEN) Receiving Somewhat Positive Press Coverage, Study Shows” was reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://weekherald.com/2017/12/14/apollo-endosurgery-apen-given-daily-news-sentiment-rating-of-0-17.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply